TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Walking test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sP Selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hopkins Verbal Learning Test - Revised
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of subjects with adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of CSF proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency volume charts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Required No Platelet Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and feasibility of BM-MNC treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Endocardial left ventricular electromechanical mapping (LVEMM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight reduction (BMI improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Dose Limiting Toxicities (DLT) in Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in total atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Retinal Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Retinal Pigment Epithelium (RPE) Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Photoreceptor Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-prandial glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Patients Achieving ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Observed and laboratory-confirmed safety
Endpoint domain: Adverse events/effects
Primary endpoint: Expiratory Flow Limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Driving Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Absolute Time Spent Off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hemoglobin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response rate (CR + PR + MR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of bone inflammation evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinician-Administered PTSD Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protocol compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: QTcF Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-Cause Mortality by Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Glycosylated Hemoglobin (Hba1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low-density lipoprotein-cholesterol (LDL-c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with treatment-emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of Participants With Local Reactions By Severity Within 14 Days of Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of Participants With Systemic Reactions By Severity Within 14 Days of Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations From Treatment Due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of new permanent pacemaker implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Characterization of keratinocyte populations after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Neuropsychiatric Inventory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1, Day 8, and Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difficulty of working
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Aldrete Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Anesthetic Discharge Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fit To PACU Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of Testosterone Serum Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Remission or improvement of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lipids including triglyceride and cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of participants undergoing pulmonary CT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Action Research Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction termination interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum cortisol-peak 30 min after ACTH-stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reports of Adverse Events or Study Discontinuations
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of Posiphen and Its Metabolites in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Posiphen and Its Metabolites in Cerebrospinal Fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional Synthesis Rate of Aβ40 in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in grams of fruit and vegetables consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total duration of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death due to cancer
Endpoint domain: Mortality/survival
Primary endpoint: death due to recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Alignment of mechanical axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications during and post procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of readmission and/or triage visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Need for additional antihypertensive therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of clinically significant changes in serum biomarker levels in a standard serum chemistry panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nephrotic syndrome remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving a 75% reduction in PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate of Static Physician's Global Assessment (sPGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of overall response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Time Zero to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Roland Morris Disability Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Screening performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMPs evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Patient-Reported Outcomes Measurement Information System (PROMIS) Measures of Anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score on Patient-Reported Outcomes Measurement Information System (PROMIS) Measures of Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score on Patient-Reported Outcomes Measurement Information System (PROMIS) Measures of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive malignancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Oral midazolam peak concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IV midazolam peak concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall midazolam area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient tolerance to the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients Demonstrating Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: subjective assessment of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rates of Staphylococcus Aureus Acquisition
Endpoint domain: Adverse events/effects
Primary endpoint: Vasculitis score 2003 (BVAS 2003)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of subjects with adverse events and/or dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of specific morbid indicators of disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relationship between various biomarkers and disease severity and progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and efficacy of currently used and new UCD therapies
Endpoint domain: Adverse events/effects
Primary endpoint: Oral feeding outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Norethindrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric Mean Ratio of the Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norethindrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in rate of fatigue status
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in other CFS symptoms
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Incidence of biopsy proven acute rejection (BPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative morphine requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cardiovascular effects of cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative change in response markers related to bone metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average length of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Improved Glasgow Coma Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Crestal Bone Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Simple Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Attention Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression to Type 2 Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of PENTAXIM™ Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: mean change in forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: fatty acid kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: adiponectin metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fracture and Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Operative Sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Secondary Caries
Endpoint domain: Adverse events/effects
Primary endpoint: Scar Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety (complications)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean area under the curve for conjunctival redness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in maternal hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in immunological activity of the disease measured by specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in patient symptoms assessed by validated questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of microperimetric parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three-month Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change of MSISQ15
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ST segment elevation from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ulcer pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence pad weight test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained viral response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mechanical Axial Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LFPs records at 3 months after implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LFPs records at 12 months after implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in vertigo intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Newborn bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: Unanticipated ICU admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Paced auditory Serial Attention Test (PASAT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Work Ability Index (WAI)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of expression of Filamin A (FLNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of blood diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Movement time (MT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total displacement (TD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of peak velocity (PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infusion related safety
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of perioperative hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Variation in daytime ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Servings of fruit and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bispectral index value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behaviour of the growth plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Scale for the assessment and rating of ataxia - SARA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants With New Arrests
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With New Incarcerations
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients that died after 15 years
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with seroma
Endpoint domain: Adverse events/effects
Primary endpoint: combined adverse maternal outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Solicited Injection Site (Local) Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Lot Consistency: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Following FluBlok Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Positive Cell Culture/Culture-Confirmed Influenza Like Illness as Defined by Centers for Disease Control and Prevention (CDC-ILI)
Endpoint domain: Adverse events/effects
Primary endpoint: Dose adjustments
Endpoint domain: Adverse events/effects
Primary endpoint: interleukin 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tumor necrosis factor alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mortality and lung/heart-lung transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Walking distance (6-min walk)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic and gas exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assistive Device Weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of All-implanted Subjects Achieving Monocular Best Corrected Distance Visual Acuity (BCDVA) of 0.3 logMAR or Better at Month 12 Postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Best-case Subjects Achieving Monocular BCDVA of 0.3 logMAR or Better at Month 12 Postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Adverse Events (Ocular and Nonocular, Serious and Nonserious), Including Secondary Surgical Interventions (SSIs) - Study Eye
Endpoint domain: Adverse events/effects
Primary endpoint: Time in Minutes for 50% of the Ingested Meal to Empty the Stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes